Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

ntrolled study of 446 patients at 44 international sites is designed to assess the TAXUS moderate-release paclitaxel-eluting coronary stent system in reducing restenosis in high-risk patients, including de novo lesions with overlapping stents, lesions 26 mm or greater in length and small vessels. Lesion size ranged from 18 - 40 mm in length and 2.5 - 3.75 mm in diameter. TAXUS VI is the first randomized, controlled clinical trial to demonstrate durability of drug-eluting stents in complex lesions at four years. Follow-up included 98 percent of the patients enrolled at four years.

The study's results demonstrate a continued significant reduction in target lesion revascularization (TLR, or retreatment rate) as compared to the bare-metal stent control group at four years. The four-year TLR rate was 12.9 percent for the TAXUS Stent group, as compared with 21.4 percent for the control group (P=0.0082 (only two TLR events were reported between three and four years for the TAXUS Stent group)). The rate of patients living free of TLR events was 87.1 percent at four years for the TAXUS Stent group, as compared to 78.6 percent for the bare-metal stent control group.

The four-year results for TAXUS VI support long-term safety with the increased levels of paclitaxel in the moderate-release formulation used in the study. Even with an in vitro dosing rate 8-10 times greater than the commercialized slow-release formulation, no compromise in safety was observed. The TAXUS Stent group continues to report no new stent thrombosis after two years with a low 2.4 percent cardiac death rate.

Boston Scientific launched the slow-release formulation TAXUS Express2 paclitaxel-eluting coronary stent system in Europe and other international markets in 2003 and in the United States in 2004. The Company launched the slow-release formulation TAXUS(R) Liberte(TM) paclitaxel-eluting coronary stent system in Europe and other international markets in 2005. The TAXUS Express modera
'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:5/17/2013)... 17, 2013 Oramed Pharmaceuticals Inc. ... drug delivery systems, announced today that the United States ... Investigational New Drug application(IND) for ORMD-0801, its oral insulin ... the FDA clearance to proceed," stated Nadav ... is a major milestone for Oramed and we look ...
(Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
(Date:5/16/2013)... SYDNEY , May 16, 2013  HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support technologies that ... that CEO Doug Godshall is scheduled ... 11:00 a.m. EDT on Monday, May 20, 2013.  The conference ... York Hotel. A live webcast of the Company,s ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2
... , CARY, N.C., Nov. 20 Cornerstone Therapeutics Inc. ... on acquiring, developing and commercializing significant products primarily for ... had received a Warning Letter from the Food and ... tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) ...
... , HARRISBURG, Pa., Nov. 20 The Department ... priority groups that did not have previous access to the vaccine. , ... Friday,s clinic hours are from 2 p.m. to 8 p.m. Hours on ... Nov. 22, the clinics will operate from 2 p.m. to 8 p.m. ...
Cached Medicine Technology:Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 2Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 3Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2
(Date:5/18/2013)... California (PRWEB) May 18, 2013 Online watch ... be Rolex watch owners at a fraction of ... of luxury timepieces in the world, buyers are urged to ... compared to buying a Rolex watch from a brick-and-mortar store, ... owned Rolex watches priced at unbelievable rates. Although some ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay ... latest edition of what is considered the "bible" of ... changes continues. "This is unprecedented, the amount of ... president-elect of the American Psychiatric Association (APA). "It,s been ... is. You have to evaluate it and then make ...
(Date:5/18/2013)... a few extra cups of coffee each month might ... known as primary sclerosing cholangitis (PSC), a new study ... Minn., found that drinking coffee was associated with a ... to cirrhosis of the liver, liver failure and biliary ... relationship. "While rare, PSC has extremely detrimental ...
(Date:5/18/2013)... Orlando, FL (May 18, 2013) The use ... for a colonoscopy, according to new research presented ... process, which begins days in advance of the ... preparation medication to be taken at strict intervals. ... for doctors to see cancer and precancerous polyps ...
(Date:5/18/2013)... is associated with a reduced risk of primary ... Clinic research shows. The findings were being presented ... Orlando, Fla. , PSC is an inflammatory ... inflammation and subsequent fibrosis that can lead to ... cancer. , "While rare, PSC has extremely detrimental ...
Breaking Medicine News(10 mins):Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New smartphone application improves colonoscopy preparation 2
... brain seen in people with Alzheimer's disease has been ... their cognitive abilities and become unusually forgetful. ,The ... who may develop Alzheimer's disease.Alzhiemer’s disease results in memory ... in the USA are estimated to suffer from this ...
... of Disease in Childhood recently published a study which proves ... hand-eye coordination of toddlers.// ,The trial was done ... fish oil/olive oil supplements from 20th week of their pregnancy ... and those who did not routinely eat more than two ...
... encephalopathy may need to get cooler at the top, to ... during birth. Such babies can now be helped with a ... damage. This product has been approved by the Food and ... device with the brand name of ‘Cool-Cap’ may be a ...
... the rules governing the private educational institutions in the ... ,The state cabinet decided to adopt the new rules ... an official said here. ,The school managements ... students, pay prescribed and timely salaries to teaching and ...
... study has indicated that inflammatory bowel disease in women could ... times.// , ,Diseases such as Crohn's disease and ulcerative ... babies or premature babies. Yet, the 'silver lining' exists in ... certainly reduced the risks. ,The St. Mary's ...
... January issue of the medical journal Otolaryngology- Head and Neck ... permanent long-term hearing loss that can be caused by exposure ... measured the impact of “impulse noise” (short bursts of acoustic ... by using short-term exposure to the impulse noise generated by ...
Cached Medicine News:Health News:Novel Brain Scan to Diagnose Alzheimer's Disease 2Health News:Novel Brain Scan to Diagnose Alzheimer's Disease 3Health News:Fish Oil Improves Toddler’s Hand-eye Coordinatio 2
Disposable tracheostomy care tray....
Disposable tracheostomy care tray....
... Has the Right Solution For Your Tracheostomy ... and care tray features the latest components ... important infection control task. Designed by clinicians, ... needs of each patient and caregiver. All ...
... Has the Right Solution For Your Tracheostomy ... and care tray features the latest components ... important infection control task. Designed by clinicians, ... needs of each patient and caregiver. All ...
Medicine Products: